[The EMBARK trial: The use of enzalutamide in biochemically recurrent prostate cancer after primary therapy].
Saved in:
| Title: | [The EMBARK trial: The use of enzalutamide in biochemically recurrent prostate cancer after primary therapy]. |
|---|---|
| Transliterated Title: | EMBARK Trial: Der Einsatz von Enzalutamid bei biochemisch rezidivierendem Prostatakarzinom nach Primärtherapie. |
| Authors: | Shelan M; Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, 3010, Bern, Schweiz. mohamed.shelan@insel.ch., Mathier E; Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, 3010, Bern, Schweiz., Aebersold DM; Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, 3010, Bern, Schweiz., Wiegel T; Department of Radiation Oncology, University Hospital Ulm, Ulm, Deutschland. |
| Source: | Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] [Strahlenther Onkol] 2025 Jun; Vol. 201 (6), pp. 666-668. Date of Electronic Publication: 2025 Feb 21. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Urban & Vogel Country of Publication: Germany NLM ID: 8603469 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1439-099X (Electronic) Linking ISSN: 01797158 NLM ISO Abbreviation: Strahlenther Onkol Subsets: MEDLINE; In Process |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
